ସଲିଫେନାସିନ

ସଲିଫେନାସିନ
Clinical data
Trade names	Vesicare, Vesicare LS
Synonyms	YM905
AHFS/Drugs.com	monograph
MedlinePlus	a605019
data	US DailyMed: Solifenacin;
Pregnancy; category	AU: B3 ; US: C (Risk not ruled out) ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	90%
Protein binding	98%
Metabolism	CYP3A4
Metabolites	Glucuronide, N-oxide, others
Elimination half-life	45 to 68 hours
Excretion	Kidney (69.2%) and fecal (22.5%)
Identifiers
	IUPAC name (3R)-1-Azabicyclo[2 2 2]oct-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate;
Chemical and physical data
Formula	C23H26N2O2
Molar mass	୩୬୨.୪୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5;
	InChI InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1 ; Key:FBOUYBDGKBSUES-VXKWHMMOSA-N ;
(verify)

ସଲିଫେନାସିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଭେସିକେୟାର, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅତସକ୍ରିୟ ମୁତ୍ରାଶୟ ଏବଂ ନ୍ୟୁରୋଜେନିକ୍ ଡିଟ୍ରୁସରର ଅତ୍ୟଧିକ ସକ୍ରିୟତାର(NDO) ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୧] ଏହା ମୂତ୍ର ଅସଞ୍ଜମତା, ବାରମ୍ବାର ମୂତ୍ର ତ୍ୟାଗ ଓ ଅନିଚ୍ଛାକୃତ ମୂତ୍ରତ୍ୟାଗ ସମସ୍ୟାରେ ସାହାଯ୍ୟ କରିପାରେ । ^[୨] ଏହାର ଉପକାରିତା ଏହି ଶ୍ରେଣୀର ଅନ୍ୟାନ୍ୟ ଔଷଧ ପରି ଦେଖାଯାଏ । ^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ । ^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଶୁଖିଲା ପାଟି, କୋଷ୍ଠକାଠିନ୍ୟ ଏବଂ ମୂତ୍ରନଳୀ ସଂକ୍ରମଣ ଅନ୍ତର୍ଭୁକ୍ତ । ^[୧] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ୟୁରିନାରି ରିଟେନସନ, କ୍ୟୁଟି ବିସ୍ତାର, ହାଲୁସିନେସନ୍, ଗ୍ଲୁକୋମା, ଏବଂ ଆନାଫାଇଲାକ୍‌ସିସ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ । ^[୪] ^[୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ସୁରକ୍ଷିତ କି ନାହିଁ ତାହା ଅସ୍ପଷ୍ଟ ରହିଛି । ^[୪] ଏହା ଆଣ୍ଟିମ୍ୟୁସ୍କାରିନିକ୍ ଶ୍ରେଣୀର ଅଟେ ଏବଂ ବ୍ଲାଡର ସଂକୋଚନ ହ୍ରାସ କରି କାର୍ଯ୍ୟ କରିଥାଏ । ^[୪]

୨୦୦୪ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ପାଇଁ ସଲିଫେନାସିନ ଅନୁମୋଦିତ ହୋଇଥିଲା । ^[୧] ^[୫] ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସର ଯୋଗାଣ ୨୦୧୯ ସୁଦ୍ଧା ମୂଲ୍ୟ ୨୮ ପାଉଣ୍ଡ ଥିଲା । ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୩୭୦ ଡଲାର ଅଟେ | ^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୧୭ ମସିହାରେ ଏହା ୨୮୩ ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ଏକ ନିୟୁତରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା | ^[୭] ^[୮]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ "Solifenacin Succinate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 2019-04-02. Retrieved 2019-03-17.
↑ ^୨.୦ ^୨.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 761. ISBN 9780857113382.
↑ "[93] Are claims for newer drugs for overactive bladder warranted?". Therapeutics Initiative. 22 April 2015. Archived from the original on 2 April 2019. Retrieved 17 March 2019.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Solifenacin Succinate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 2019-04-02. Retrieved 2019-03-17.
↑ "Drug Approval Package: VesiCare (Solifenacin Succinate) NDA #021518". U.S. Food and Drug Administration (FDA). Archived from the original on 29 November 2020. Retrieved 26 May 2020.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
↑ "Solifenacin Succinate - Drug Usage Statistics". ClinCalc. Archived from the original on 4 July 2020. Retrieved 11 April 2020.

[AHFS2019-1] ୧.୦ ^୧.୧ ^୧.୨ "Solifenacin Succinate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 2019-04-02. Retrieved 2019-03-17.

[BNF76-2] ୨.୦ ^୨.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 761. ISBN 9780857113382.

[TI93-3] "[93] Are claims for newer drugs for overactive bladder warranted?". Therapeutics Initiative. 22 April 2015. Archived from the original on 2 April 2019. Retrieved 17 March 2019.

[autogen1-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Solifenacin Succinate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 2019-04-02. Retrieved 2019-03-17.

[FDA_approval-5] "Drug Approval Package: VesiCare (Solifenacin Succinate) NDA #021518". U.S. Food and Drug Administration (FDA). Archived from the original on 29 November 2020. Retrieved 26 May 2020.

[NADAC2019-6] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[7] "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.

[8] "Solifenacin Succinate - Drug Usage Statistics". ClinCalc. Archived from the original on 4 July 2020. Retrieved 11 April 2020.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]